Antibody-Drug Conjugates (ADCs)

抗体-药物偶联物 (ADC) 是一种通过化学接头与高细胞毒性小分子 (有效载荷) 偶联的人源化或人类单克隆抗体,是一种新型治疗形式,具有在癌症化疗中实现范式转变的巨大潜力。这种基于抗体的分子平台能够选择性地将强效的细胞毒性有效载荷递送至目标癌细胞,与传统化疗相比,可提高疗效、降低全身毒性并实现更佳的药代动力学 (PK)/药效学 (PD) 和生物分布。

ADC 的所有三个组成部分,即抗体、细胞毒性剂和连接它们的接头,都是其设计中的关键元素。抗体部分应该对选择性表达在癌细胞上或相对于正常细胞在癌细胞上过度表达的细胞表面靶分子具有特异性。ADC 的有效载荷必须具有高度的细胞毒性,这样它才能在 ADC 分布到实体肿瘤组织后达到细胞内浓度时杀死肿瘤细胞,并且因为只有有限数量的有效载荷可以连接到抗体分子(通常平均每个抗体 3-4 个有效载荷)而不会严重损害其生物物理和药代动力学特性。细胞毒性化合物包括卡奇霉素的衍生物,一类通过引起 DNA 双链断裂杀死细胞的高细胞毒性烯二炔抗生素,以及强效抗有丝分裂微管破坏剂、多拉司他汀 10(奥瑞他汀)和美登素的衍生物。

ADC 的第三个重要组成部分是形成有效载荷和抗体之间化学连接的接头。连接子在循环中应足够稳定,以允许有效载荷在循环中分布到组织(包括实体肿瘤组织)时保持与抗体的连接,但一旦 ADC 被癌细胞吸收,应允许有效释放活性细胞杀伤剂。连接子可分为可裂解连接子和不可裂解连接子。

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.

All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.

The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.

共 145种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
ABBV-154

ABBV-154 是一种抗 TNF 抗体-药物偶联物 (ADC),由人源化抗体 Adalimumab (MS-V49701) 与糖皮质激素受体调节剂 (MS-U87328) 连接组成,可用于类风湿关节炎、克罗恩病和风湿性多肌痛的研究。

96.23%
ABBV-154
ABBV-3373

ABBV-3373 是一种抗 TNF 抗体-药物偶联物 (ADC),由人源化 TNF 抗体 Adalimumab (MS-V49701) 与糖皮质激素受体激动剂 (MS-G76969) 连接组成,可用于类风湿关节炎的研究。

98.78%
ABBV-3373
ABBV-706

ABBV-706 是一种靶向 SEZ6 的拓扑异构酶 1 (topoisomerase 1) 抑制剂抗体药物偶联物 (ADC),由 Linker-Payload 偶联物 (MS-J68294) 和 Anti-SEZ6 Antibody (SC17) (MS-M87141) 组成,能够抑制癌细胞增殖并诱导 DNA 损伤及 G2/M 期阻滞,对小细胞肺癌 (SCLC)、神经内分泌肿瘤 (NEN) 和中枢神经系统 (CNS) 肿瘤表现出高效的抗肿瘤活性。

99.71%
ABBV-706
ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine

ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine 是 MEDI3726 (MS-Y66238) 的同型对照抗体药物偶联物,带有 C214S 轻链及 C226V/C229V 重链铰链突变,其毒性分子和 linker 偶联物为 Tesirine (MS-J52084),可用于前列腺癌、转移性去势抵抗性前列腺癌的研究。

ADC Control Human IgG1 (C214S light chain, C226V and C229V heavy chain)-Tesirine
ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR4)

ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) 是一种化合物-抗体比为 4 的对照 ADC,由 Human IgG1(D356E/L358M) kappa, Isotype Control (MS-I40685) 与 LNK4-S (MS-E23427) 偶联而成,是 Farletuzumab-LNK4-S (DAR4) (MS-H93010) 的同型对照。

ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR4)
ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR8)

ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) 是一种药物-抗体比为 8 的对照 ADC,由不与 FRα 特异性结合的 Human IgG1 (D356E/L358M) kappa, Isotype Control (MS-I40685) 与 LNK4-S (MS-E23427) 组成,并作为 Farletuzumab-LNK4-S (DAR8) (MS-D78642) 的同型对照。

ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR8)
ADC Control Human IgG1-Deruxtecan (DAR 4)

ADC Control Human IgG1-Deruxtecan (DAR 4) 是一种人源单克隆抗体,作为 ADC human IgG1-Deruxtecan 的同型对照,可抑制 DNA topoisomerase I,其抗体部分为 Human IgG1 kappa, Isotype Control (MS-E04981),ADC 毒性分子和 linker 部分为 Deruxtecan (MS-M03436)。

95.61%
ADC Control Human IgG1-Deruxtecan (DAR 4)
ADC Control Human IgG1-Deruxtecan (DAR 8)

ADC Control Human IgG1-Deruxtecan (DAR 8) 是一种人源单克隆抗体,作为 ADC human IgG1-Deruxtecan 的同型对照,可抑制 DNA topoisomerase I,其抗体部分为 Human IgG1 kappa, Isotype Control (MS-E04981),ADC 毒性分子和 linker 部分为 Deruxtecan (MS-M03436)。

99.32%
ADC Control Human IgG1-Deruxtecan (DAR 8)
ADC Control Human IgG1-DL-01

ADC Control Human IgG1-DL-01 是一种由 ADC 抗体 Human IgG1 lambda1, Isotype Control (MS-J32982) 与 linker-payload DL-01 formic (MS-X22888) 组成的抗体-活性分子偶联物 (ADC)。

ADC Control Human IgG1-DL-01
ADC Control human IgG1-DM1

ADC Control human IgG1-DM1 是一种 ADC 对照,由 Human IgG1 kappa, Isotype Control (MS-E04981) 与连接子-药物偶联物 SMCC-DM1 (MS-Y26665) 组成。

97.58%
ADC Control human IgG1-DM1
ADC Control Human IgG1-DM4

ADC Control Human IgG1-DM4 是 ADC Human IgG1-DM4 的同型对照,其抗体部分为 Human IgG1 kappa, Isotype Control (MS-E04981),ADC 毒性分子和 linker 部分为 SPDB-DM4 (MS-P61103)。

ADC Control Human IgG1-DM4
ADC Control Human IgG1-ED04

ADC Control human IgG1-ED04 是一种由 Human IgG1 kappa, Isotype Control (MS-E04981) 与 ADC 毒素 ED04 (MS-K53129) 组成的 ADC 对照,可作为 BL-B01D1 (MS-I37954) 的同型对照。

Control
96.07%
ADC Control Human IgG1-ED04

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础